Salute e Benessere
Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
Discover the rheumatoid arthritis new treatment @
According to DelveInsight's estimates, the US accounted for around diagnosed prevalent cases of rheumatoid arthritis in 2024. These cases are further expected to increase by 2034.
Current therapies such as biological DMARDs showed promising results in treating rheumatoid arthritis patients, and market penetration is expected to be more in the future and expected to drive market growth. Oral classes such as JAKi are also expected to contribute to the rheumatoid arthritis market growth.
Emerging therapies like (Cyxone), (AstraZeneca), (Eli Lilly and Company), (Rise Therapeutics), (TNF Pharmaceuticals), (SciRhom), and others are being developed for safe and efficacious treatment options.
Since the introduction of the first biologic therapy over two decades ago, the treatment landscape for rheumatoid arthritis has undergone a remarkable transformation. The market today is well-established, featuring multiple blockbuster therapies. The approval of paved the way for subsequent and other classes of rheumatoid arthritis treatments. Biologics, especially anti-TNFs, remain deeply entrenched as the standard of care, and despite the approval of several new therapeutic classes, none have achieved comparable influence or market penetration.
Approved treatments for rheumatoid arthritis include , , , and , among others. Meanwhile, emerging therapies such as , and , , , , and are being developed to provide safer and more effective treatment alternatives. Notably, has discontinued its Phase I trial for autoimmune disorders in Austria .
The market potential for rheumatoid arthritis therapies remains substantial; are currently used for rheumatoid arthritis treatment. Major pharmaceutical and biotechnology companies, including and , dominate the space. Many of these industry leaders have fortified their market positions through robust patent protections, effectively limiting biosimilar and generic competition.
To know more about rheumatoid arthritis treatment options, visit @
Some of the rheumatoid arthritis drugs in the pipeline include (Cyxone), (Taiho Pharmaceutical), and (AstraZeneca), (Eli Lilly and Company), (Rise Therapeutics), (TNF Pharmaceuticals), and others.
is an orally administered drug with a distinct mechanism of action that selectively targets inflammatory macrophages — white blood cells that play a central role in driving inflammation, tissue destruction, and clinical manifestations of rheumatoid arthritis (RA). It is considered particularly effective during the onset and flare-ups of RA, with strong potential to prevent joint damage and disease progression. The drug is currently in Phase II clinical trials.
is a novel, highly selective Bruton's tyrosine kinase (BTK) inhibitor. By targeting BTK, the drug may help control inflammation and bone erosion by directly modulating effector cells, such as B cells, macrophages, and osteoclasts, involved in RA. A Phase II clinical trial is underway in Japan to assess the safety and efficacy of TAS5315 in combination with methotrexate in patients with RA who show an inadequate response to methotrexate alone.
is a first-in-class bispecific antibody designed to simultaneously inhibit peptidyl arginine deiminases (PADs) 2 and 4 — enzymes responsible for protein citrullination. This process generates autoantigens driving the autoimmune response in RA. By blocking PAD2 and PAD4, AZD1163 seeks to prevent the formation of these autoantigens.
is a small interfering RNA (siRNA) therapy targeting human Complement Factor B (CFB), a critical component of the alternative complement pathway. By suppressing hepatic CFB expression, AZD6912 aims to reduce systemic complement activation, thereby mitigating inflammation and tissue damage associated with rheumatoid arthritis.
The anticipated launch of these emerging therapies are poised to transform the rheumatoid arthritis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the rheumatoid arthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for rheumatoid arthritis @
Rheumatoid arthritis is a long-term, inflammatory autoimmune disorder that causes progressive and damaging polyarthritis. It is marked by persistent pain and joint deterioration, typically spreading from the smaller, distal joints to larger, proximal ones. The condition arises when the immune system mistakenly attacks the body's own healthy tissues, though its exact causes remain unclear. RA occurs more frequently in women, who account for roughly 75% of all cases, and it most commonly develops between the ages of 30 and 50.
The rheumatoid arthritis epidemiology section provides insights into the historical and current rheumatoid arthritis patient pool and forecasted trends for the leading markets. In the US, the total prevalent cases of rheumatoid arthritis were nearly in 2024.
The rheumatoid arthritis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving rheumatoid arthritis therapeutics market trends @
report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including , among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key juvenile rheumatoid arthritis companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PsA companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/rheumatoid-arthritis-market-to-surge-by-2034-as-next-generation-biologics-and-jak-inhibitors-gain-traction--delveinsight-302603568.html